8,548,956 Shares Conversion Exercise - 18.62% of Total Issued Shares


  • On April 28, 2026, conversion rights were exercised for the 3rd series perpetual convertible bonds (remaining balance of 1,205 million KRW), resulting in the issuance of 8,548,956 new shares
  • Conversion price was 3,025 KRW, exercise amount was 25,860 million KRW, representing a dilution of 18.62% of total issued shares (45,902,856 shares)
  • Remaining unconverted bond balance is 1,205,485,519 KRW, corresponding to 398,507 possible additional shares

KOSDAQ Filing Information


  • Exercise of Conversion Rights
  • Company: Genome & (314130)
  • Submission: Genome & Company
  • Under KRX KOSDAQ Market Division

  • Shares: 35,118,811
  • Price: 6,510 KRW
  • Market Cap: 228.6 B KRW